Anil K Chandraker MD
Kidney & Pancreas Transplantation
Associate Professor, Medicine, Harvard Medical School
Join to View Full Profile
55 Lake Ave NWorcester, MA 01655
Phone+1 508-334-3155
Dr. Chandraker is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General HospitalFellowship, Nephrology, 1995 - 1999
University of Glasgow Faculty of MedicineClass of 1987
Certifications & Licensure
MA State Medical License 1999 - 2026
Awards, Honors, & Recognition
- President American Society of Transplantation, 2016-2017
- Fellow (ASNF) American Society of Nephrology
Clinical Trials
- Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Start of enrollment: 2006 Mar 01
- BK Treatment Study Start of enrollment: 2009 Feb 01
- Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation Start of enrollment: 2011 Sep 01
Publications & Presentations
PubMed
- 6 citationsAn Exosomal mRNA Urine Test for Detection and Risk Stratification of Human Kidney Transplant Rejection.Rania El Fekih, Kurt Franzen, James Hurley, Brian C Haynes, Tamara Merhej
Kidney International Reports. 2025-04-01 - 1 citationsPerceptions of Palliative Care Among Patients With Kidney Allograft Dysfunction: A Qualitative Study.Cameron E Comrie, Katherine He, Jolene Wong, Anil K Chandraker, Naoka Murakami
Kidney Medicine. 2024-12-01 - 13 citationsA Randomized Trial Comparing Imlifidase to Plasmapheresis in Kidney Transplant Recipients With Antibody-Mediated Rejection.Fabian Halleck, Georg A Böhmig, Lionel Couzi, Lionel Rostaing, Gunilla Einecke
Clinical Transplantation. 2024-07-01
Press Mentions
Olaris, Inc Receives PLA Code from the American Medical Association for myOLARIS-KTdx, a Non-Invasive Urine-Based Assay to Assess Immune Status Post Kidney TransplantJanuary 22nd, 2025- AlloVir Reports Full-Year 2022 Financial Results and 2023 OutlookFebruary 17th, 2023
- AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant RecipientsJune 7th, 2022
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
